KR20180114955A - 류마티스 관절염의 치료를 위한 조성물 및 방법 - Google Patents

류마티스 관절염의 치료를 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20180114955A
KR20180114955A KR1020187028624A KR20187028624A KR20180114955A KR 20180114955 A KR20180114955 A KR 20180114955A KR 1020187028624 A KR1020187028624 A KR 1020187028624A KR 20187028624 A KR20187028624 A KR 20187028624A KR 20180114955 A KR20180114955 A KR 20180114955A
Authority
KR
South Korea
Prior art keywords
antibody
subject
rheumatoid arthritis
administration
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187028624A
Other languages
English (en)
Korean (ko)
Inventor
데보라 바우어
알렉산더 바디
닐 그레이엄
용 린
제니 파리노
라울 파텔
자넷 반 아델스버그
휴버트 반 훅스트라텐
Original Assignee
사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에
리제너론 파아마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16305253.3A external-priority patent/EP3216461A1/en
Application filed by 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에, 리제너론 파아마슈티컬스, 인크. filed Critical 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에
Priority to KR1020237019726A priority Critical patent/KR20230093522A/ko
Publication of KR20180114955A publication Critical patent/KR20180114955A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020187028624A 2016-03-07 2017-03-07 류마티스 관절염의 치료를 위한 조성물 및 방법 Ceased KR20180114955A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237019726A KR20230093522A (ko) 2016-03-07 2017-03-07 류마티스 관절염의 치료를 위한 조성물 및 방법

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP16305253.3A EP3216461A1 (en) 2016-03-07 2016-03-07 Compositions and methods for treating rheumatoid arthritis
EP16305253.3 2016-03-07
EP16170664.3 2016-05-20
EP16170664 2016-05-20
EP16306111.2 2016-09-05
EP16306111 2016-09-05
PCT/US2017/021149 WO2017155990A1 (en) 2016-03-07 2017-03-07 Compositions and methods for treating rheumatoid arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237019726A Division KR20230093522A (ko) 2016-03-07 2017-03-07 류마티스 관절염의 치료를 위한 조성물 및 방법

Publications (1)

Publication Number Publication Date
KR20180114955A true KR20180114955A (ko) 2018-10-19

Family

ID=58387910

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187028624A Ceased KR20180114955A (ko) 2016-03-07 2017-03-07 류마티스 관절염의 치료를 위한 조성물 및 방법
KR1020237019726A Ceased KR20230093522A (ko) 2016-03-07 2017-03-07 류마티스 관절염의 치료를 위한 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237019726A Ceased KR20230093522A (ko) 2016-03-07 2017-03-07 류마티스 관절염의 치료를 위한 조성물 및 방법

Country Status (18)

Country Link
US (1) US20190100585A1 (enExample)
EP (1) EP3426295A1 (enExample)
JP (2) JP7166925B2 (enExample)
KR (2) KR20180114955A (enExample)
CN (1) CN109069642A (enExample)
AU (2) AU2017229364A1 (enExample)
BR (1) BR112018067851A2 (enExample)
CA (1) CA3016880A1 (enExample)
CL (1) CL2018002559A1 (enExample)
CR (1) CR20180465A (enExample)
EA (1) EA201892005A1 (enExample)
IL (2) IL308539A (enExample)
MX (2) MX2018010815A (enExample)
PH (1) PH12018501894A1 (enExample)
SG (2) SG11201807614SA (enExample)
TN (1) TN2018000312A1 (enExample)
TW (3) TW202419103A (enExample)
WO (1) WO2017155990A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
WO2019105450A1 (zh) * 2017-11-30 2019-06-06 百奥泰生物制药股份有限公司 一种治疗il-6相关疾病的人源化抗体的液体制剂
KR20210049871A (ko) * 2018-08-29 2021-05-06 리제너론 파아마슈티컬스, 인크. 류마티스성 관절염을 갖는 대상체를 치료하기 위한 방법 및 조성물
TWI860325B (zh) * 2019-01-31 2024-11-01 法商賽諾菲生物技術公司 用於治療幼年原發性關節炎之組成物及方法
BR112021021077A2 (pt) * 2019-04-24 2021-12-14 E Zilberstein Moshe Métodos de diagnóstico e tratamento de artrite reumatoide
MX2021014892A (es) * 2019-06-04 2022-06-27 Sanofi Biotechnology Composiciones y metodos para el tratamiento del dolor en sujetos con artritis reumatoide.
WO2023020563A1 (en) * 2021-08-18 2023-02-23 Bio-Thera Solutions, Ltd. Liquid formulations comprising high concentrations humanized antibodies for treating il-6 related diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
CA2385745C (en) * 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
PL2041177T3 (pl) 2006-06-02 2012-09-28 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
GB0718684D0 (en) * 2007-09-24 2007-10-31 Roche Products Ltd Treatment method
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
CA2930615C (en) * 2013-11-22 2023-04-04 Sanofi Biotechnology Compositions for the treatment of rheumatoid arthritis and methods of using same

Also Published As

Publication number Publication date
JP7745529B2 (ja) 2025-09-29
CL2018002559A1 (es) 2019-03-01
TN2018000312A1 (en) 2020-01-16
TW202419103A (zh) 2024-05-16
IL261515B2 (en) 2024-04-01
KR20230093522A (ko) 2023-06-27
WO2017155990A1 (en) 2017-09-14
BR112018067851A2 (pt) 2019-02-05
JP7166925B2 (ja) 2022-11-08
CR20180465A (es) 2019-03-04
AU2024203011A1 (en) 2024-07-11
EP3426295A1 (en) 2019-01-16
PH12018501894A1 (en) 2019-05-15
JP2019507775A (ja) 2019-03-22
CA3016880A1 (en) 2017-09-14
NZ746988A (en) 2023-10-27
IL261515A (en) 2018-10-31
JP2023011711A (ja) 2023-01-24
SG10202012182YA (en) 2021-01-28
IL261515B1 (en) 2023-12-01
TW201808993A (zh) 2018-03-16
TW202239767A (zh) 2022-10-16
IL308539A (en) 2024-01-01
SG11201807614SA (en) 2018-10-30
AU2017229364A1 (en) 2018-10-25
TWI819435B (zh) 2023-10-21
TWI747885B (zh) 2021-12-01
EA201892005A1 (ru) 2019-02-28
MX2023014841A (es) 2024-01-15
US20190100585A1 (en) 2019-04-04
MX2018010815A (es) 2019-01-10
CN109069642A (zh) 2018-12-21

Similar Documents

Publication Publication Date Title
JP7745529B2 (ja) 関節リウマチを処置するための組成物及び方法
KR102122708B1 (ko) Ｉｌ-4ｒ 길항제 투여로 아토피성 피부염을 치료하는 방법
TWI618543B (zh) Ｉｌ-１７抗體用於製備治療強直性脊椎炎之藥物之用途
JP2017078075A (ja) 対象の選択および治療
JP7542543B2 (ja) 若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
US11491222B2 (en) Method of treating lower back pain
US20230174657A1 (en) Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same
RU2822089C2 (ru) Антитело к рецептору il-6 для лечения ювенильного идиопатического артрита
NZ746988B2 (en) Compositions and methods for treating rheumatoid arthritis
WO2025166169A1 (en) Compositions, doses, and methods for treatment of c1s mediated diseases and disorders
EP4157872A1 (en) Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same
KR20200069388A (ko) Ｉｌ-4ｒ 길항제 투여로 아토피성 피부염을 치료하는 방법

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000